GlassScriptPhysician profile
Mark Paul Strosser
NPI 1902800683
$4,313.25
in general payments reported to CMS, 2019-2025
22 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $135 · 2021: $710 · 2022: $729 · 2023: $761 · 2024: $779 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $565.43 | 2021-2025 | Cequa |
| Coopervision INC. | $523.31 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Alcon Vision LLC | $491.83 | 2019-2025 | Tryptyr, Precision7 |
| Tarsus Pharmaceuticals, INC. | $467.57 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $389.89 | 2021-2023 | Tepezza |
| Allergan, INC. | $253.36 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $251.68 | 2023-2024 | Acuvue |
| Dompe US, INC. | $176.87 | 2022-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $142.06 | 2023-2024 | Biotrue One Day, Infuse, Miebo |
| Kala Pharmaceuticals, INC. | $129.74 | 2021 | |
| Sight Sciences, INC. | $127.88 | 2021 | |
| Abbvie INC. | $124.97 | 2023 | Durysta |
| Amgen INC. | $121.85 | 2024 | |
| Rxsight INC | $118.68 | 2022 | |
| Lombart Brothers, INC. | $92.72 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $92.59 | 2019 | |
| Shire North American Group INC | $92.12 | 2019 | |
| Oyster Point Pharma, INC. | $55.71 | 2022-2024 | Tyrvaya |
| Astellas Pharma US INC | $25.22 | 2024 | Izervay |
| Halozyme INC | $24.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.87 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Strosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.